As the industry turns its attention to low-cost, easy-to-use diagnostics for developing countries, researchers at Florida Atlantic University are developing a biosensing tool that uses a smartphone and a paper microchip to screen for diseases such as HIV.
In the wake of its multibillion-dollar asset swap with Novartis, GlaxoSmithKline is doubling down on its vaccines focus. And it'll be doing that in Maryland, where it's establishing a new global R&D center.
UPenn researchers are in the early stage of developing a neural implant to help the 10 million people across the globe with traumatic brain injury improve their memory.
At the Children's Hospital of Philadelphia, researchers are looking toward biodegradable nanoparticles capable of delivering cancer drugs to neuroblastoma without harming surrounding tissue.
New York City's Anterios is developing ANT-1207, a lotion containing the active ingredient of Botox (marketed by recently acquired Allergan) that can be applied on the skin via a 10-minute massage. Anterios recently filed for a $58 million IPO with the Securities and Exchange Commission.
As med tech companies set their sights on innovative devices to treat cancer, new, miniaturized products for nonmelanoma skin cancer are gaining ground as a viable alternative to surgery.
Researchers at Northwestern University have put together a nanostructure capable of shuttling a new RNA molecule across the blood-brain barrier to reach tumor cells in mice with glioblastoma multiforme, a particularly aggressive form of brain cancer.
CRISPR Therapeutics--which was founded in Switzerland by Emmanuelle Charpentier, one of the pioneers in the field--has hired Alexion vet Bill Lundberg to head up its R&D operations in Cambridge, MA.
San Diego-based aTyr Pharma wasn't just flirting with an IPO when it announced a big $76 million round a few days ago. It had its S-1 all ready to go.
Nancy Stagliano has a very clear idea of how to plot a course for True North. Eighteen months ago the biotech CEO raised $30 million for iPierian and split its assets with the newborn True North Therapeutics. Seven months later Bristol-Myers Squibb snapped up a reorganized iPierian in a $725 million deal. Then in swift succession Stagliano raised new funds, beefed up her staff with a key hire and is now banking $35 million in a fresh venture round that will take True North into the clinic with its lead therapy for rare diseases while positioning its follow-up program for human studies.